Montgomery-Åsberg Depression Rating Scale — a validated 10-item clinician-rated scale measuring depression severity, scored from 0 (no symptoms) to 60 (severe). A 50% reduction from baseline is generally considered a treatment response; a score below 10 indicates remission. Used as a key secondary outcome measure in psilocybin depression trials including the landmark 2021 NEJM vs escitalopram study. Distinct from the QIDS-SR, which is self-reported.
MADRS (Montgomery-Åsberg Depression Rating Scale) is a validated 10-item clinician-rated scale measuring depression severity, scored from 0 (no symptoms) to 60 (severe). A 50% reduction from baseline is generally considered a treatment response; a score below 10 indicates remission. Used as a key secondary outcome measure in psilocybin depression trials including the landmark 2021 NEJM vs escitalopram study. Distinct from the QIDS-SR, which is self-reported.
See: Depression (/conditions/depression), Psilocybin vs SSRIs (/guides/psilocybin-vs-ssris).
When you see MADRS in trial results, you can interpret response (50% drop) and remission (score below 10) and compare psilocybin studies to standard depression research.